We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer.
- Authors
Messaritakis, Ippokratis; Sfakianaki, Maria; Papadaki, Chara; Koulouridi, Asimina; Vardakis, Nikolaos; Koinis, Filippos; Hatzidaki, Dora; Georgoulia, Nefeli; Kladi, Athina; Kotsakis, Athanasios; Souglakos, John; Georgoulias, Vassilis
- Abstract
<bold>Purpose: </bold>Τo evaluate the clinical relevance of CEACAM5mRNA-positive circulating tumor cells (CTCs) in patients with metastatic colorectal cancer (mCRC).<bold>Methods: </bold>Peripheral blood was obtained from 436 patients with mCRC before the initiation of systemic therapy. A second sample was obtained on treatment assessment from 296 (67.9%) patients. The detection of CEACAM5mRNA-positive CTCs was performed using a real-time PCR assay.<bold>Results: </bold>The patients' median age was 67 years and PS (EGOG 0-1) 92%; KRAS exon 2 and BRAFV600E mutated primary tumors were identified in 31.9% and 6.4% of the tested patients, respectively, whereas metastasectomy was performed in 17.7% of the patients. Circulating CEACAM5mRNA-positive CTCs were detected in 125 (28.7%) and 85 (28.7%) patients at baseline and on treatment assessment, respectively. The detection of CEACAM5mRNA-positive cells was revealed, in multivariate analysis, as an independent prognostic factor associated with decreased PFS (HR 1.6; 95% CI 1.1-2.5; p = 0.026) and OS (HR 2.2; 95% CI 1.3-3.2; p < 0.001). The detection of CEACAM5mRNA-positive CTCs in patients with KRAS and BRAFV600E mutations was correlated with shorter PFS (p = 0.041 and p = 0.022, respectively). Moreover, OS was significantly shorter in patients with CEACAM5+/KRAS mutations compared to those with CEACAM5+/KRAS wt tumors (p = 0.023).<bold>Conclusions: </bold>Detection of peripheral blood CEACAM5mRNA-positive CTCs is an adverse prognostic factor correlated with poor clinical outcome in patients with mCRC, especially in patients with KRAS and BRAF mutated tumors.
- Subjects
METASTASIS; COLON cancer; COLON cancer patients; COLON cancer treatment; MESSENGER RNA; CANCER cells
- Publication
Cancer Chemotherapy & Pharmacology, 2018, Vol 82, Issue 5, p767
- ISSN
0344-5704
- Publication type
journal article
- DOI
10.1007/s00280-018-3666-9